达克替尼联合西妥昔单抗治疗晚期非小细胞肺癌的临床疗效及生存情况分析

doi:10.3969/j.issn.1671-7171.2024.03.028

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1193 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨达克替尼联合西妥昔单抗治疗晚期非小细胞肺癌(NSCLC)的临床疗效及生存情况。【方法】204例晚期NSCLC患者,随机分为对照组和观察组,每组102例。对照组给予西妥昔单抗治疗,观察组在对照组的基础上口服达克替尼。两组患者均持续用药至疾病进展或毒性不能耐受。比较两组持续治疗3个疗程的疗效、肿瘤标志物、肺功能及药物不良反应发生情况和1年生存情况。【结果】观察组因未完成全疗程治疗脱落3例,对照组脱落5例,最终分别纳入99例和97例。观察组的临床控制率高于对照组(P<0.05)。两组治疗后的肿瘤特异性生长因子(TSGF)、细胞增殖抗原(PCNA)、癌胚抗原(CEA)均低于治疗前(均P<0.05),且观察组低于对照组(P<0.05)。两组治疗后的用力肺活量(FVC)、第一秒用力呼气容积(FEV₁)/FVC均高于治疗前(P<0.05),且观察组高于对照组(P<0.05)。两组药物不良反应总发生率比较,差异无统计学意义(P>0.05)。截至随访结束,对照组有2例失访,观察组1例失访,观察组98例患者存活62例,对照组95例患者存活47例,观察组1年总存活曲线优于对照组(P<0.05)。【结论】达克替尼联合西妥昔单抗治疗晚期NSCLC可增强抗肿瘤疗效,降低肿瘤标志物水平,改善近期生存情况。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：癌,非小细胞肺/药物疗法, 抗体,单克隆/治疗应用, 治疗结果, 存活率

Abstract：【Objective】To investigate the clinical efficacy and survival of dacomitinib combined with cetuximab in the treatment of advanced non-small cell lung cancer(NSCLC). 【Methods】A total of 204 patients with advanced NSCLC were randomly divided into the control group and the observation group, with 102 cases in each group. The control group was given cetuximab treatment, and the observation group was given dacomitinib orally in addition to cetuximab. In both groups, medication continued until disease progression or toxic intolerance. The anti-tumor efficacy, tumor marker changes, lung function and adverse drug reactions of the two groups were compared after 3 courses of continuous treatment, and the 1-year survival was also analyzed between the two groups. 【Results】In the observation group, 3 patients dropped off due to incomplete treatment, and 5 cases dropped off in the control group. Finally, 99 cases in the observation group and 97 cases in the control group were included, respectively. The clinical control rate of the observation group was higher than that of the control group(P< 0.05). The levels of tumor-specific growth factor(TSGF), cell proliferation antigen(PCNA), carcinoembryonic antigen(CEA) after treatment were lower than those before treatment. And the levels of TSGF, PCNA and CEA in the observation group after treatment were lower than those in the control group(P<0.05). The forced vital capacity(FVC) and forced expiratory volume in the first second(FEV₁) /FVC in the two groups after treatment were higher than those before treatment(P<0.05), while those in the observation group were higher after treatment(P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05). By the end of follow-up, 2 cases in the control group and 1 case in the observation group were lost to follow-up. From the 1-year survival survey, 62 of 98 patients survived in the observation group and 47 of 95 patients survived in the control group. The 1-year overall survival curve of the observation group was better than that of the control group(P<0.05). 【Conclusion】Dacomitinib combined with Cetuximab in the treatment of advanced NSCLC can enhance anti-tumor efficacy, reduce tumor marker levels, and improve short-term survival.

Key words： Carcinoma, Non-Small-Cell Lung/DT Antibodies, Monoclonal/TU Treatment Outcome Survival Rate

收稿日期: 2023-10-10

中图分类号:

R734.2

通讯作者: *E-mail:13573834683@163.com

引用本文:

李萱, 潘华, 张晓鹏, 徐歆然, 张海燕. 达克替尼联合西妥昔单抗治疗晚期非小细胞肺癌的临床疗效及生存情况分析[J]. 医学临床研究, 2024, 41(3): 420-423.
LI Xuan, PAN Hua, ZHANG Xiaopeng, et al. Clinical Efficacy and Survival Analysis of Dacomitinib Combined with Cetuximab in the Treatment of Advanced Non-small Cell Lung Cancer. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 420-423.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.03.028 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I3/420

[1] ALZOFON N, JIMENO A. Capmatinib for non-small cell lung cancer[J].Drugs Today(Barc),2021, 57(1):17-25.
[2] DOHOPOLSKI M, IYENGAR P. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy[J].Ann Palliat Med,2021, 10(5):5944-5953.
[3] SACCO A G, CHEN R, WORDEN F P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial[J].Lancet Oncol,2021, 22(6):883-892.
[4] NILSSON F O L, GAL P, HOUISSE I, et al. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer(EGFRm NSCLC) in Sweden[J].J Med Econ,2021, 24(1):447-457.
[5] 中华医学会, 中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志, 2018, 40(12):935-964.
[6] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009, 45(2):228-247.
[7] 高东宸. 药物不良反应监察指南[M]. 北京:中国医药科技出版社,1996:48-51.
[8] 段昕波, 曹晓慈, 杜东杰. 达克替尼通过抑制EGFR表达促白介素-6诱导非小细胞癌细胞株A549凋亡的效果[J].毒理学杂志, 2020, 34(1):51-56.
[9] PATY J, SANDIN R, REISMAN A, et al. The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the phase Ⅲ trial ARCHER 1050[J].Future Oncol,2021, 17(7):783-794.
[10] PISCITELLI J, CHEN J, LABADIE R R, et al. The effect of hepatic impairment on the pharmacokinetics of Dacomitinib[J].Clin Drug Investig,2022, 42(3):221-235.
[11] MOK T S, CHENG Y, ZHOU X, et al. Updated overall survival in a randomized study comparing Dacomitinib with Gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations[J].Drugs,2021, 81(2):257-266.
[12] NAKAGAWA K, MATSUMURA K, SCORY T, et al. Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population[J].Future Oncol,2021, 17(1):103-115.